Eledon Pharmaceuticals
ELDN
15 hedge funds and large institutions have $3.45M invested in Eledon Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 8 closing their positions.
2.51% less ownership
Funds ownership: 45.26% → 42.75% (-2.5%)
25% less funds holding
Funds holding: 20 → 15 (-5)
42% less capital invested
Capital invested by funds: $5.93M → $3.45M (-$2.48M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$240K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.7K |
| 3 |
HR
Hayden Royal
Charlotte,
North Carolina
|
+$7.99K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$1.68K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$201 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$273K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$166K |
| 3 |
VF
Virtu Financial
New York
|
-$25.2K |
| 4 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
-$23K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$23K |
ELDN Hedge Fund Activity: Q3 2019 in Review
15 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2019, worth a combined $3.45M — down 42% from $5.93M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ELDN and 3 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was 683 Capital Management, adding an estimated $240K. The largest seller was B. Riley Wealth Advisors, exiting entirely with an estimated $273K sold.
- 15 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2019, down from 20 in Q2 2019.
- Funds reported $3.45M of Eledon Pharmaceuticals stock for Q3 2019, down 42% quarter-over-quarter.
- 3 funds opened new Eledon Pharmaceuticals positions in Q3 2019 and 8 closed out, a net change of -5 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2019 was 683 Capital Management, an estimated $240K added.
- The largest Eledon Pharmaceuticals seller in Q3 2019 was B. Riley Wealth Advisors, an estimated $273K sold.
Based on aggregated 13F filings for Q3 2019.